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Results: A total of 76 patients (61±15 years, 35 male/41 female) had a mean BNP (pg/
ml) of 2766± 1398 (SD) of whom 50 (66%) had LVEF >40 and only 17 (22%) had VOL.
All patients had a recent history of cancer- 34 (45%) had a hematological malignancy
and 42 (55%) had a solid tumor. 43 patients (57%) had evidence of sepsis. Of these 43
patients, 40 did not have VOL and 35 had LVEF>40. The BNP values, although all ele-
vated, were higher in VOL (3463±1439, n=17) versus NO VOL (2565±1332, n=59)
p<0.05. Similarly, BNP values were higher if LVEF<40 (3273±1474, n=26) versus
LVEF>40 (2502±1294, n=50), p<0.05 by ANOVA.
Conclusion: Markedly elevated BNP values obtained on cancer patients admitted with
multiple co-morbidities may not reliably indicate VOL or reflect LV dysfunction. In patients
with cancer and infectious complications, therapeutic decisions may need to be guided
more by clinical evidence as opposed to laboratory evidence of HF or VOL. It is possible
that other factors, such as IL-6 or other cytokines, may stimulate BNP release in the
absence of significant VOL or perhaps interfere with the standard assay giving errone-
ously high values.
1049-117 B-Type Natriuretic Peptide Is a Biochemical Predictor of 
Myocardial Contractile Reserve During Dobutamine 
Stress Echocardiogram
Ann Tong, Daniel Lenihan, Vivjay Divakaran, Jessica M. Tristan, Mona Nemer, Joseph 
Swafford, Gregory Geisler, Mary Vooletich, Beverly Handy, Jean-Bernard Durand, 
University of Texas, M.D. Anderson Cancer Center, Houston, TX
Dobutamine Stress Echocardiography (DSE) is used to assess myocardial contractile
reserve (CR) in ischemic and dilated cardiomyopathy (CMP). A higher CR is associated
with improved prognosis and LVEF with optimal therapy. No data is available in patients
with chemotherapy-induced CMP. Technical limitations due to imaging may reduce the
diagnostic ability of DSE. Brain Natriuretic Peptide (BNP), a neurohormone secreted
from the ventricle in response to volume overload, may provide additional predictive
power to DSE.
We hypothesized that BNP can be used as a biochemical marker for CR and may
improve diagnostic capability of DSE. BNP levels were obtained at baseline and peak
infusion during DSE in 42 patients (23 men, 19 women) with LVEF < 45%. Baseline
demographics: mean age 61±14 yrs, prior chemotherapy 67%, ischemic heart disease
34%, hypertension 36%, diabetes 12%, and NYHA class 2.3±0.9. Patients were catego-
rized based on response of BNP during DSE: Group 1 (n=22, BNP falls) and Group 2
(n=20, BNP rises). See Table 1. With linear regression analysis, there was a significant
inverse correlation between changes in BNP and LVEF pre and post DSE (r=0.6,
p<0.001). 
BNP can identify CR in conjunction with DSE and may be helpful in technically difficult 
studies. A decrease in BNP after DSE is strongly correlated with the presence of CR as 
shown by an increase in LVEF. In chemotherapy-induced CMP, a condition generally con-
sidered irreversible, BNP in conjunction with DSE may predict improvement of cardiac 
function.
1049-118 N-Terminal Pro-Brain Natriuretic Peptide and Urinary 
Albumin Excretion Is Independent Predictors of All 
Cause Mortality in the General Population
Caroline Kistorp, Ilan Raymond, Frants Pedersen, Jens Faber, Per Hildebrandt, 
Frederiksberg University Hospital, Frederiksberg, Denmark
Background: N-terminal proBNP (NT-proBNP) and urinary albumin excretion is known
important risk factors for mortality in patients with chronic heart failure (CHF) and diabe-
tes mellitus, respectively. It is unclear whether these unconventional risk factors are inde-
pendent predictors of all cause mortality in the general population.
Methods: A total of 658 subjects (age 51-91 years), were consecutively recruited from 4
general practitioners in the Frederiksberg municipality. All subjects underwent echocar-
diography, measuring left ventricular ejection fraction (LVEF), and plasma NT-proBNP
and urinary albumin/creatinine ratio (A/C ratio) were measured at baseline. Mean follow-
up time was 48 months. Using multivariate Cox proportional hazard models, the prognos-
tic value of the upper quartile of plasma NT-proBNP and urinary A/C ratio was evaluated
in two models: Model 1 (total population). Model 2 (after exclusion of patients with known
heart failure or LVEF <=50 %, as well as, diabetes by history or HbA1c >= 6.1 %).
Results: During follow-up there were 55 (8.4 %) deaths from any cause in the total pop-
ulation (n = 658). Plasma levels of NT-proBNP and urinary A/C ratio in the upper quartile,
was associated with increased risk for total mortality. For NT-proBNP, hazard ratio (HR)
was 3.6 (95% CI: 1.6-6.7, p < 0.0001); for urinary A/C ratio, HR was 2.6 (95% CI: 1.4-4.9,
p=0.002). In model 2 (n = 495) mortality rates were 5.3 %. For NT-proBNP, HR was 2.8
(95% CI: 1.3-6.2, p=0.009); for urinary A/C ratio, HR was 5.1 (95% CI: 1.8-13.9,
p=0.0019), after adjustment for age, gender, LVEF and established risk factors in both
models. Median urinary A/C ratio (mg/g) and plasma NT-proBNP (pmol/l) levels in sub-
jects who died was 20 mg/g (4-274), and 94.0 pmol/l (18.3-1633.2), compared with 6 mg/
g (3-66) and 30.1 pmol/l (5.2-202.6) in survivors, p < 0.0001 for both.
Conclusion: Plasma NT-proBNP and urinary albumin are independent risk factors for
total mortality in the general population. Even when excluding patients with conditions
associated with increased plasma NT-proBNP and urinary albumin excretion, both
unconventional risk factors remained strong prognostic predictors.
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1050-120 Echocardiographic and Angiographic Correlations in 
Cardiogenic Shock
M. Joshua Berkowitz, Shannon Harkness, Judith Hochman, Michael Picard, Timothy 
Sanborn, Norma Keller, James Slater, New York University Hospital, New York, NY
Objectives: We investigated the correlation between echocardiographic and angio-
graphic core lab data in patients with cardiogenic shock (CS) complicating AMI.
Background: In patients with CS complicating AMI, both echocardiographic and angio-
graphic findings are used to aid diagnosis, determine prognosis, and guide management.
The purpose of this study of the SHOCK trial is to identify relationships between the
angiographic and echocardiographic features of patients with CS. Such an analysis may
provide insights into the etiology and treatment of CS.
Methods/Results: Of 302 randomized patients, a pre-revascularization echocardiogram
and angiogram was available in 119 patients. The correlations between almost all echo
and angiographic parameters collected within 4 hours and greater than 4 hours of each
other were similar. Although the median ejection fraction (EF) derived by echo and LV
angiogram was identical, 29.5%, this significant positive correlation was weak (R2=.209,
p=.019) as was the significant negative correlation between EF and angiographic jeop-
ardy scores (R2=.145, p=.001). Although the presence of left main obstruction (>50%
stenosis) was associated with lower LVEF (26% vs.31%, p= .031) there was only a trend
for decreasing EF with number of diseased vessels. Patients with a higher number of dis-
eased vessels had worse MR by echo (p=.005). There was a significant but weak associ-
ation between LV gram MR grade and echo MR severity (R2=.162, p=.015), but there
was no association between culprit vessel and degree of MR. Patients with TIMI grade 0/
1 were more likely to have impaired LV function (p=.029). Collateral flow to the culprit
vessel was not associated with improved EF. There was a trend towards an increased
incidence of LV thrombus in LAD culprit vessels (p=.060).
Conclusions: Higher angiographic jeopardy scores and low TIMI flow scores are associ-
ated with worse LV function but collateral flow to the culprit vessel is not associated with
improved EF by echo. Worse CAD is associated with more severe MR. Both echo and
angiography are valuable and result in similar estimated EF's in a large cohort however
there is wide variation between the techniques in individual patients.
1050-121 Echocardiographic, Electrophysiological, Histological, 
and Serological Recovery During Left Ventricular Assist 
Device Support
Steve Xydas, Jason Cohen, Yoshifumi Naka, Donna M. Mancini, Marco DiTullio, Amanda 
D. Arnold, Chuck Ng, Mehmet C. Oz, Simon Maybaum, Columbia University College of 
Physicians and Surgeons, New York, NY
Background: Mechanical unloading during left ventricular assist device (LVAD) support
may lead to cardiac recovery, however, clinical markers of recovery have yet to be identi-
fied. We sought to define the echocardiographic (echo), EKG, serological and histologi-
cal changes during device support.
Methods: LVAD patients underwent monthly evaluation, including echo, EKG and serum
BNP measurement. Paired myocardial tissue samples from implant and explant were
analyzed.
Results: 32 LVAD patients were prospectively followed. Duration of heart failure was
47.3 ± 99.1 months and duration of support was 103.2 ± 85 days. Left ventricular ejection
fraction (LVEF) and end-diastolic diameter significantly improved at 30 days as compared
to pre-LVAD, with no further improvement with longer periods of support. At 30 and 60
days, QTc and QRS were significantly decreased from pre-LVAD. There was a marked
reduction in BNP, myocyte size, and collagen deposition during LVAD support. In screen-
ing for markers of recovery, the decrease in QTc correlated with LVEF at 30 days (R = -
0.993, p < .01). Interestingly, changes in QRS correlated with the drop in myocardial col-
lagen deposition (R = -0.976, p < .01). No study patients had sufficient recovery for
device explantation.
Conclusions: We demonstrate echo, EKG, histologic, and serological improvement dur-
ing LVAD support. Recovery is evident at 30 days and is sustained through 90 days of
support. Further prospective data collection may yield important markers of recovery.
Table 1
Change in 
BNP(pg/ml)
Pre-DSE 
LVEF(%)
Post- 
DSE  
LVEF (%)
Change in 
LVEF(%)*
Group 1 (fall in BNP) -110±90 35±9 49±11 14±5
Group 2 (rise in BNP) 68±84 33±9 38±12 4±8
all data is mean ± SD
* change in LVEF inversely correlates with change in BNP, <0.001
